Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.
July 01, 2019

Dr. Tim Franson Rejoins FaegreBD in Indianapolis

Faegre Baker Daniels is pleased to announce that Dr. Tim Franson has rejoined the firm’s Indianapolis office as a principal in the Health & FDA group. Dr. Franson also will work significantly from the Washington, D.C. office.  

Dr. Franson has extensive experience in all pre- and post-approval phases of pharmaceutical development (small and large molecule) relating to interactions with FDA for policy and product issues, as well as interactions with global regulators. His practice provides clinical and regulatory professional services for drug and biologics development (strategy, planning, training and issues management) post-approval advice (REM's, labeling, compliance) and due diligence for venture capital firms.

“We are delighted that Tim is bringing his unparalleled regulatory expertise back to the firm,” noted Health & FDA group leader Dave Zook.  “Our clients in industry, research organizations, and patient advocacy communities will be able to apply his deep experience to their efforts to advance new therapies.”

Dr. Franson previously served as Vice President of Global Regulatory Affairs at Eli Lilly & Co.  after which he was a principal with Faegre Baker Daniels Consulting (2010-14).  He also held the position of President of USP, the standards-setting organization for the biopharmaceutical sector and is currently the board chair of the Critical Path Institute.  From 2014-19, Dr. Franson was Chief Medical Officer of YourEncore.

Related Professionals

Related Legal Services

Related Industries

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.